Physician profile
Roger E Bowles
NPI 1063473965
$6,396.65
in general payments reported to CMS, 2019-2025
38 companies · $704 in 2025
The $704 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,025 · 2020: $1,142 · 2021: $1,093 · 2022: $543 · 2023: $1,082 · 2024: $808 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,593.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $793.28 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $786.87 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $715.21 | 2019-2024 | Xarelto |
| Amgen INC. | $562.15 | 2019-2024 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $527.25 | 2019-2025 | Airsupra, Nexium, Farxiga |
| Novo Nordisk INC | $313.42 | 2019-2025 | Wegovy |
| Lilly USA, LLC | $281.25 | 2020-2025 | Mounjaro, Kisunla, Emgality |
| Merck Sharp & Dohme LLC | $225.64 | 2019-2024 | Dificid, Gardasil 9, Pneumovax 23 |
| Glaxosmithkline, LLC. | $185.62 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.09 | 2020-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $174.64 | 2019-2024 | |
| Astellas Pharma US INC | $173.33 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $166.81 | 2021-2025 | |
| Allergan, INC. | $143.02 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $122.42 | 2020-2023 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Bowles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.